A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Study sponsor: Ascentage Pharma Group Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-08Estimated
Enrollment · participants344Estimated
Source updated2026-07-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.